These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 28030526)

  • 1. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
    Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A
    Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
    Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.
    Bouckenooghe A; Bailleux F; Feroldi E
    Hum Vaccin Immunother; 2019; 15(1):72-79. PubMed ID: 30230947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
    Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
    Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.
    Feroldi E; Capeding MR; Boaz M; Gailhardou S; Meric C; Bouckenooghe A
    Hum Vaccin Immunother; 2013 Apr; 9(4):889-97. PubMed ID: 23442823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary immunization of infants and toddlers in Thailand with Japanese encephalitis chimeric virus vaccine in comparison with SA14-14-2: a randomized study of immunogenicity and safety.
    Feroldi E; Pancharoen C; Kosalaraksa P; Chokephaibulkit K; Boaz M; Meric C; Hutagalung Y; Bouckenooghe A
    Pediatr Infect Dis J; 2014 Jun; 33(6):643-9. PubMed ID: 24717964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term immunogenicity of the SA14-14-2 Japanese encephalitis (JE) vaccine (CD.JEVAX®) booster following chimeric JE (IMOJEV®) vaccine priming in Thai children.
    Chotpitayasunondh T; Suntarattiwong P; Yoksan S
    Hum Vaccin Immunother; 2024 Dec; 20(1):2407663. PubMed ID: 39353860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
    Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
    Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines.
    Capeding MR; Alberto ER; Bouckenooghe A; Laot TM; Chansinghakul D; Monfredo C; Machabert T; Feroldi E
    J Infect Dis; 2018 Jan; 217(4):567-571. PubMed ID: 29325161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a single dose of a live attenuated Japanese encephalitis chimeric virus vaccine in Vietnam: A single-arm, single-center study.
    Vu TD; Nguyen QD; Tran HTA; Bosch-Castells V; Zocchetti C; Houillon G
    Int J Infect Dis; 2018 Jan; 66():137-142. PubMed ID: 29081368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization.
    Feroldi E; Boaz M; Yoksan S; Chokephaibulkit K; Thisyakorn U; Pancharoen C; Monfredo C; Bouckenooghe A
    J Infect Dis; 2017 Jan; 215(2):221-227. PubMed ID: 27815383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®) in children.
    Chokephaibulkit K; Houillon G; Feroldi E; Bouckenooghe A
    Expert Rev Vaccines; 2016; 15(2):153-66. PubMed ID: 26588242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
    Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
    Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
    Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
    Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term immunity to live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year phase II study in healthy adults.
    Nasveld PE; Ebringer A; Elmes N; Bennett S; Yoksan S; Aaskov J; McCarthy K; Kanesa-thasan N; Meric C; Reid M
    Hum Vaccin; 2010 Dec; 6(12):1038-46. PubMed ID: 21150279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.
    Dubischar KL; Kadlecek V; Sablan JB; Borja-Tabora CF; Gatchalian S; Eder-Lingelbach S; Kiermayr S; Spruth M; Westritschnig K
    Pediatr Infect Dis J; 2017 Sep; 36(9):898-904. PubMed ID: 28430748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.